{"id":399397,"date":"2020-12-14T16:18:24","date_gmt":"2020-12-14T21:18:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=399397"},"modified":"2020-12-14T16:18:24","modified_gmt":"2020-12-14T21:18:24","slug":"mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/","title":{"rendered":"MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group"},"content":{"rendered":"
\n

YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has further expanded its NexoBrid\u00ae<\/sup> global presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group (GAG), an international conglomerate based in the United Arab Emirates (UAE), an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns. Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval, which is expected within a year.<\/p>\n

\u201cWe are truly excited to partner with GAG to bring NexoBrid to the UAE,\u201d said Sharon Malka, Chief Executive Officer of MediWound. \u201cThis partnership is an important consequence of the Abraham Accords Peace Agreement signed recently between Israel and the UAE. GAG, through its healthcare arm, Gaelan Medical Trade LLC, has extensive knowledge and experience in wound care and has a strong reach into the major clinical institutions in the UAE. We are proud to enter into our first partnership in the Middle East, and believe that, together with GAG, we will be able to open up new opportunities for NexoBrid across the region, providing burn specialists with a new paradigm for the treatment of severe burns, which can improve patients’ lives and the quality of their care.\u201d<\/p>\n

Ghassan Aboud, Chairman of Ghassan Aboud Group stated, \u201cWe are pleased to partner with MediWound to bring NexoBrid to our markets in the UAE. Our goal is always to pioneer, excel and make an impact, which we have been doing so for 26 years now. I am certain that with our extensive distribution network and market reach, and with MediWound’s innovative drug we will be able to improve the standard of care of burn patients and I strongly believe NexoBrid will be an instrumental part of the future treatment for burn patients everywhere.”<\/p>\n

\n About NexoBrid<\/strong>\n <\/p>\n

NexoBrid (concentrate of proteolytic enzymes enriched in Bromelain) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns within four hours of application without harming viable tissue. NexoBrid is approved in the\u00a0European Union\u00a0and other international markets and has been designated as an orphan biologic drug in\u00a0the United States,\u00a0European Union, and other international markets.\u00a0Vericel\u00a0Corporation holds an exclusive license for North American commercial rights to NexoBrid. In\u00a0January 2019,\u00a0MediWound\u00a0announced positive top-line results from the acute phase of the pivotal Phase 3 U.S. clinical study (DETECT) of NexoBrid in adult patients with deep partial-and full-thickness thermal burns up to 30 percent of total body surface area. The study met its primary endpoint of complete eschar removal compared to gel vehicle as well as all secondary endpoints compared to standard of care (SOC), including shorter time to eschar removal, a lower incidence of surgical eschar removal and lower blood loss during eschar removal. Safety endpoints, including the key safety endpoint of non-inferiority in time to complete wound closure compared with patients treated with SOC, were also achieved. In addition, the twelve-month and twenty-four-month follow-up safety data of cosmesis and function were found to be comparable between the treatment and SOC arms, and no new safety signals were observed. On\u00a0September 16, 2020, the FDA accepted for review the Company\u2019s Biologics License Application (BLA) for eschar removal (debridement) in adults with deep partial-thickness and\/or full-thickness thermal burns and was assigned a Prescription Drug User Fee Act (PDUFA) target date of June 29, 2021.<\/p>\n

\n About Ghassan Aboud Group <\/strong>\n <\/p>\n

Ghassan Aboud Group is an international conglomerate that has been engaged in several key business sectors including health care, automotive, hospitality, real estate, retail, catering, logistics, pastoral, trade and distribution and media for more than two decades.<\/p>\n

Headquartered in the United Arab Emirates, GAG\u2019s business operations are complemented by offices in Australia, Belgium, Jordan and Turkey. Ghassan Aboud Group believes that productivity, innovation and transformation require community engagement and ensures that its exclusive portfolio operates in a corporate conscious and a responsible manner making people the number one priority behind its vision \u201cBeing at the forefront of excellence\u201d.<\/p>\n

Gaelan Medical, GAG\u2019s UAE based healthcare and beauty distribution business follows a mission of care and cure and is dedicated to support healthcare providers with world-class solutions to better serve communities across the GCC region. Gaelan medical with its experienced management team, caters to diverse healthcare needs including, pharmaceuticals, medical consumables, medical equipment and beauty products. The company’s flexibility and strong financial capabilities of its parent company GAG makes it the preferred partner-of-choice and one stop solution for the region.<\/p>\n

\n About\u00a0MediWound Ltd.<\/strong>\n <\/p>\n

MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound\u2019s first innovative biopharmaceutical product, NexoBrid, non-surgically and rapidly removes burn eschar without harming viable tissue. The product has received marketing authorization from the European Medicines Agency as well as the Israeli, Argentinian, South Korean, Russian and Peruvian Ministries of Health for eschar removal (debridement) in adults with deep partial-thickness and\/or full-thickness thermal burns. On June 29, 2020, a biological license application (BLA) was submitted to the U.S. FDA and was assigned a Prescription Drug User Fee Act (PDUFA) target date of June 29, 2021. MediWound\u2019s second innovative product, EscharEx\u00ae is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid. In two Phase 2 studies, EscharEx has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications. For more information, please visit www.mediwound.com<\/a>.<\/p>\n

\n
\n Cautionary Note Regarding Forward-Looking Statements<\/em>
\n <\/strong>\n <\/p>\n

\n MediWound\u00a0caution you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements.\u00a0 Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties and factors, all of which are difficult to predict and many of which are beyond our control.\u00a0 Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release.\u00a0 These statements are often, but are not always, made through the use of words or phrases such as \u201canticipates,\u201d \u201cintends,\u201d \u201cestimates,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201ccontinues,\u201d \u201cbelieve,\u201d \u201cguidance,\u201d \u201coutlook,\u201d \u201ctarget,\u201d \u201cfuture,\u201d \u201cpotential,\u201d \u201cgoals\u201d and similar words or phrases, or future or conditional verbs such as \u201cwill,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cmay,\u201d or similar expressions.<\/em>\n <\/p>\n

\n Specifically, this press release contains forward-looking statements concerning the anticipated progress, development, objectives, expectations, and commercial potential of. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated with product development activities; the timing or likelihood of regulatory approvals; the ability to successfully develop and commercialize NexoBrid, including its commercial growth potential and the market demand for the product; competitive developments; whether FDA will accept all or part of the BLA and provide marketing approval for NexoBrid in\u00a0the United States; the impact of applicable laws and regulations; and the\u00a0uncertainties associated with the scope, scale and duration of the impact of the COVID-19 pandemic. For example, we are\u00a0unable to predict how the pandemic will affect the overall healthcare infrastructure, including the pace with which governmental agencies, such as the FDA, will review and approve regulatory submissions. Additional government-imposed quarantines and requirements to \u201cshelter at home\u201d or other incremental mitigation efforts also may impact our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of NexoBrid in the future.<\/em>\n <\/p>\n

\n These and other significant factors are discussed in greater detail in MediWound\u2019s annual report on Form 20-F for the year ended\u00a0December 31, 2019, filed with the\u00a0Securities and Exchange Commission\u00a0(\u201cSEC\u201d) on\u00a0February 25, 2020, Quarterly Reports on Form 6-K and other filings with the\u00a0SEC\u00a0from time-to-time. These forward-looking statements reflect MediWound\u2019s current views as of the date hereof and\u00a0MediWound\u00a0undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law.\u00a0<\/em>\n <\/p>\n\n\n\n\n\n\n
\n Contacts:<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
Boaz Gur-Lavie\u00a0<\/td>\nJeremy Feffer<\/td>\n<\/tr>\n
Chief Financial Officer<\/td>\nManaging Director, LifeSci Advisors<\/td>\n<\/tr>\n
MediWound Ltd.<\/td>\n212-915-2568<\/td>\n<\/tr>\n
\n ir@mediwound.com<\/a>\n <\/td>\n\n jeremy@lifesciadvisors.com<\/a>\u00a0<\/td>\n<\/tr>\n<\/table>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has further expanded its NexoBrid\u00ae global presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group (GAG), an international conglomerate based in the United Arab Emirates (UAE), an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns. Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval, which is expected within a year. \u201cWe are truly excited to partner with GAG to bring NexoBrid to the UAE,\u201d said Sharon Malka, Chief Executive … <\/p>\n

Continue reading “MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-399397","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has further expanded its NexoBrid\u00ae global presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group (GAG), an international conglomerate based in the United Arab Emirates (UAE), an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns. Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval, which is expected within a year. \u201cWe are truly excited to partner with GAG to bring NexoBrid to the UAE,\u201d said Sharon Malka, Chief Executive … Continue reading "MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-14T21:18:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTg2MSMzODgwNDMzIzIwMTY4NjE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group\",\"datePublished\":\"2020-12-14T21:18:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\\\/\"},\"wordCount\":1446,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMTg2MSMzODgwNDMzIzIwMTY4NjE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\\\/\",\"name\":\"MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMTg2MSMzODgwNDMzIzIwMTY4NjE=\",\"datePublished\":\"2020-12-14T21:18:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMTg2MSMzODgwNDMzIzIwMTY4NjE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMTg2MSMzODgwNDMzIzIwMTY4NjE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/","og_locale":"en_US","og_type":"article","og_title":"MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group - Market Newsdesk","og_description":"YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has further expanded its NexoBrid\u00ae global presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group (GAG), an international conglomerate based in the United Arab Emirates (UAE), an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns. Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval, which is expected within a year. \u201cWe are truly excited to partner with GAG to bring NexoBrid to the UAE,\u201d said Sharon Malka, Chief Executive … Continue reading \"MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-14T21:18:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTg2MSMzODgwNDMzIzIwMTY4NjE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group","datePublished":"2020-12-14T21:18:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/"},"wordCount":1446,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTg2MSMzODgwNDMzIzIwMTY4NjE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/","name":"MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTg2MSMzODgwNDMzIzIwMTY4NjE=","datePublished":"2020-12-14T21:18:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTg2MSMzODgwNDMzIzIwMTY4NjE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTg2MSMzODgwNDMzIzIwMTY4NjE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-arab-emirates-with-ghassan-aboud-group\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=399397"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399397\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=399397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=399397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=399397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}